Q32 Bio Reports $7.6 Million Net Loss in Q1 2026, Focuses on Bempikibart Development

Q32 Bio Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $7.6 million, a decrease from the $11.0 million loss recorded in the same period of 2025. The company’s total operating expenses for the quarter were $7.7 million, down from $12.2 million year-over-year, primarily due to reduced research and development costs, which fell to $3.2 million from $7.1 million. This reduction was attributed to lower spending on the bempikibart program and the cessation of expenses related to the ADX-097 program following its sale to Akebia Therapeutics in late 2025.

In terms of liquidity, Q32 Bio reported cash and cash equivalents of $50.8 million as of March 31, 2026, an increase from $48.3 million at the end of 2025. The company raised $10.4 million through a registered direct offering in February 2026 and entered into an at-the-market (ATM) offering program, which allows for the potential sale of up to $14.2 million in common stock. Subsequent to the quarter, Q32 Bio sold 2.3 million shares under the ATM, generating an additional $13.8 million in proceeds.

Strategically, Q32 Bio has focused on advancing its lead product candidate, bempikibart, which is currently in Phase 2 clinical trials for alopecia areata. The company has completed two Phase 2a trials and is preparing for further development, having received Fast Track designation from the FDA for this indication. The company also announced the completion of enrollment in Part B of the SIGNAL-AA trial, with topline data expected in mid-2026. The sale of ADX-097 to Akebia has allowed Q32 Bio to streamline its focus on bempikibart and its proprietary tissue-targeted complement inhibitor platform.

Operationally, Q32 Bio has seen a reduction in its employee headcount due to a corporate restructuring in early 2025, which has contributed to lower personnel-related costs. The company continues to evaluate its research and development pipeline, with plans to invest significantly in advancing its clinical programs. However, it acknowledges the need for additional capital to support ongoing operations and development efforts, as it does not expect to generate revenue from product sales in the near term. The company anticipates that its current cash reserves, combined with future financing efforts, will be sufficient to fund operations into the first half of 2028, although it remains subject to various risks and uncertainties inherent in the biotechnology sector.